BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

811 related articles for article (PubMed ID: 26980726)

  • 21. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
    Serrano E; Carnicer MJ; Lasa A; Orantes V; Pena J; Brunet S; Aventín A; Sierra J; Nomdedéu JF
    Leuk Res; 2008 Jun; 32(6):944-53. PubMed ID: 18206229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia.
    Gao X; Lin J; Gao L; Deng A; Lu X; Li Y; Wang L; Yu L
    PLoS One; 2015; 10(4):e0124241. PubMed ID: 25860287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AML1-ETO needs a partner: new insights into the pathogenesis of t(8;21) leukemia.
    Kuchenbauer F; Feuring-Buske M; Buske C
    Cell Cycle; 2005 Dec; 4(12):1716-8. PubMed ID: 16294039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
    Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secreted-frizzled related protein 1 is a transcriptional repression target of the t(8;21) fusion protein in acute myeloid leukemia.
    Cheng CK; Li L; Cheng SH; Ng K; Chan NP; Ip RK; Wong RS; Shing MM; Li CK; Ng MH
    Blood; 2011 Dec; 118(25):6638-48. PubMed ID: 22031861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Core binding factor acute myeloid leukemia.
    Paschka P
    Semin Oncol; 2008 Aug; 35(4):410-7. PubMed ID: 18692691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
    Yin JA; O'Brien MA; Hills RK; Daly SB; Wheatley K; Burnett AK
    Blood; 2012 Oct; 120(14):2826-35. PubMed ID: 22875911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice.
    Wang YY; Zhao LJ; Wu CF; Liu P; Shi L; Liang Y; Xiong SM; Mi JQ; Chen Z; Ren R; Chen SJ
    Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2450-5. PubMed ID: 21262832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome of Core Binding Factor Acute Myeloid Leukemia in Children: A Single-Center Experience.
    Mansoor N; Jabbar N; Arshad U; Maqsood S; Habib MA; Raza MR
    J Pediatr Hematol Oncol; 2020 Aug; 42(6):e423-e427. PubMed ID: 32496446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.
    Park SH; Lee HJ; Kim IS; Kang JE; Lee EY; Kim HJ; Kim YK; Won JH; Bang SM; Kim H; Song MK; Chung JS; Shin HJ
    Ann Lab Med; 2015 May; 35(3):288-97. PubMed ID: 25932436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Genetic abnormalities in core binding factor acute myeloid leukemia].
    Ishikawa Y
    Rinsho Ketsueki; 2017; 58(8):991-998. PubMed ID: 28883285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute myeloid leukemia with a novel t(8;21) variant: paracentric inversion-associated ins(21;8).
    Lee JH; Wan TS; Ha JS
    Leuk Lymphoma; 2014 Feb; 55(2):441-3. PubMed ID: 23672346
    [No Abstract]   [Full Text] [Related]  

  • 33. Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML).
    Agrawal M; Schwarz P; Giaimo BD; Bedzhov I; Corbacioglu A; Weber D; Gaidzik VI; Jahn N; Rücker FG; Schroeder T; Kindler T; Wattad M; Götze K; Lübbert M; Salwender H; Ringhoffer M; Lange E; Koller E; Thol F; Heuser M; Ganser A; Bullinger L; Paschka P; Döhner H; Geiger H; Borggrefe T; Döhner K; Oswald F
    Leukemia; 2020 Feb; 34(2):630-634. PubMed ID: 31462736
    [No Abstract]   [Full Text] [Related]  

  • 34. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.
    Marková J; Marková J; Trnková Z; Michková P; Maaloufová J; Starý J; Cetkovský P; Schwarz J
    Leuk Lymphoma; 2009 Sep; 50(9):1448-60. PubMed ID: 19603346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology.
    Marcucci G; Caligiuri MA; Bloomfield CD
    Cancer Invest; 2000; 18(8):768-80. PubMed ID: 11107447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.
    Jahn N; Terzer T; Sträng E; Dolnik A; Cocciardi S; Panina E; Corbacioglu A; Herzig J; Weber D; Schrade A; Götze K; Schröder T; Lübbert M; Wellnitz D; Koller E; Schlenk RF; Gaidzik VI; Paschka P; Rücker FG; Heuser M; Thol F; Ganser A; Benner A; Döhner H; Bullinger L; Döhner K
    Blood Adv; 2020 Dec; 4(24):6342-6352. PubMed ID: 33351131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Core binding factor acute myeloid leukaemia and c-KIT mutations.
    Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
    Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
    Pollard JA; Alonzo TA; Gerbing RB; Ho PA; Zeng R; Ravindranath Y; Dahl G; Lacayo NJ; Becton D; Chang M; Weinstein HJ; Hirsch B; Raimondi SC; Heerema NA; Woods WG; Lange BJ; Hurwitz C; Arceci RJ; Radich JP; Bernstein ID; Heinrich MC; Meshinchi S
    Blood; 2010 Mar; 115(12):2372-9. PubMed ID: 20056794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
    Allen C; Hills RK; Lamb K; Evans C; Tinsley S; Sellar R; O'Brien M; Yin JL; Burnett AK; Linch DC; Gale RE
    Leukemia; 2013 Sep; 27(9):1891-901. PubMed ID: 23783394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.